Kilitch Drugs (India) Ltd
Pharmaceuticals & Biotechnology | Small Cap
Kilitch Drugs demonstrates a mixed financial performance. The company shows strong growth and profitability, driven by substantial increases in revenue, operating profit, and earnings per share. Its solvency is excellent, indicating a low debt burden and strong equity. However, efficiency and liquidity pose some concerns. While inventory management is efficient, asset turnover and receivable collection are less so. Liquidity ratios suggest potential challenges in meeting short-term obligations. The company's coverage ratios are mixed, with strong interest coverage offset by the absence of dividend coverage. Overall, Kilitch Drugs exhibits promising growth and profitability, but needs to address efficiency and liquidity to ensure long-term financial stability. The healthcare industry is subject to regulatory changes and market competition, both of which could impact future performance.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio2.40
- Profitability Ratio9.80
- Efficiency Ratio4.67
- Coverage Ratio6.80
- Solvency Ratio10.00
- Liquidity Ratio5.36
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBullish
- 1 WeekBullish
- 1 MonthBullish
Kilitch Drugs demonstrates a mixed financial performance. The company shows strong growth and profitability, driven by substantial increases in revenue, operating profit, and earnings per share. Its solvency is excellent, indicating a low debt burden and strong equity. However, efficiency and liquidity pose some concerns. While inventory management is efficient, asset turnover and receivable collection are less so. Liquidity ratios suggest potential challenges in meeting short-term obligations. The company's coverage ratios are mixed, with strong interest coverage offset by the absence of dividend coverage. Overall, Kilitch Drugs exhibits promising growth and profitability, but needs to address efficiency and liquidity to ensure long-term financial stability. The healthcare industry is subject to regulatory changes and market competition, both of which could impact future performance.
Overall Valuation Score
P/E RATIO (TTM)
20.05
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
21.54
P/B RATIO
2.32
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
2.74
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
13.98
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹185.86 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company demonstrates excellent growth across all key metrics, including revenue, operating profit, earnings per share, assets, and net income. This indicates a strong growth trajectory and effective management strategies. The weighted average calculation confirms this positive trend, reflecting a consistent and robust growth performance.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 67.65 | 22.81 | 10 | 28.57 | 18.69 |
| Operating Profit Growth Rate | 100 | 80 | 33.33 | 33.33 | 15.62 |
| Earnings Per Share (EPS) Growth | 99.08 | 41.94 | 35.39 | 82.97 | 13.11 |
| Asset Growth Rate | 3.45 | 4.76 | 9.09 | 30.42 | 46.33 |
| Net Income Growth Rate | 50 | 33.33 | 75 | 78.57 | 20 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The financial ratios of the company indicate areas of concern. Adjusted Earnings Per Share, Book Value Per Share and Capital Expenditure is not up to the mark. Dividend Per Share (DPS) is zero. There is a need to focus on improving key financial metrics to enhance overall financial health and investor confidence. The weighted average calculation highlights the areas needing improvement and strategic adjustments.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 2.5 | 3.24 | 7.53 | 12.76 | 8.38 |
| Cash Earnings Per Share (Cash EPS) | 5 | 7.5 | 10.62 | 17.5 | 9.71 |
| Book Value Per Share | 87.5 | 95 | 110 | 126.25 | 80 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 8 | 4 | 6 | 47 | 100 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company demonstrates excellent profitability, with strong gross profit margin, return on capital employed, return on equity, return on assets, operating margin, and net margin. This indicates effective cost management, efficient asset utilization, and strong earnings generation. The weighted average calculation confirms this positive trend, reflecting a consistently robust profitability performance.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 7.02 | 10 | 13.64 | 14.65 | 14.04 |
| Return on Capital Employed (ROCE) | 6 | 10 | 13 | 16 | 14 |
| Return on Equity (ROE) | 4.29 | 5.26 | 7.95 | 12.38 | 10.71 |
| Return on Assets (ROA) | 4.76 | 8.18 | 10 | 10.22 | 8.08 |
| Operating Margin | 8.77 | 12.86 | 15.58 | 16.16 | 15.74 |
| Net Margin | 5.26 | 5.71 | 9.09 | 12.63 | 12.77 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios present a mixed picture. While inventory turnover and days sales in inventory are excellent, indicating efficient inventory management, fixed asset turnover, receivables turnover, receivable days, and capital turnover are below average. This suggests potential issues with asset utilization and collection efficiency. The weighted average calculation highlights the need for improvements in these areas to optimize overall efficiency.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1.75 | 2.19 | 2.48 | 3.09 | 3.51 |
| Inventory Turnover Ratio | 23.56 | 36 | 44.33 | 17.89 | 15.04 |
| Receivables Turnover Ratio | 3.56 | 2.95 | 2.63 | 2.68 | 2.29 |
| Days Sales in Inventory Ratio | 15.49 | 10.14 | 8.23 | 20.4 | 24.27 |
| Receivable Days | 102.53 | 123.73 | 138.78 | 136.19 | 159.39 |
| Capital Turnover Ratio | 0.81 | 0.92 | 0.88 | 0.86 | 0.69 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios present a mixed performance. While the interest coverage ratio is excellent, indicating a strong ability to meet interest obligations, the equity dividend coverage ratio is poor, reflecting the absence of dividend payouts. This suggests that the company is prioritizing debt obligations over shareholder returns. The weighted average calculation highlights the need for a more balanced approach to coverage management.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 11 | 3.4 | 4.17 | 7.8 | 7.5 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits excellent solvency, with low debt ratios and a high equity ratio. This indicates a strong financial structure and a minimal reliance on debt financing. This provides a stable base for future growth and reduces the risk of financial distress. The weighted average calculation confirms this positive trend, reflecting a consistently strong solvency position.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 | 0.12 | 0.17 |
| Debt to Equity Ratio | 0 | 0 | 0 | 0.14 | 0.2 |
| Equity Ratio | 1 | 1 | 1 | 0.88 | 0.83 |
| Debt To Asset Ratio | 0 | 0 | 0 | 0.09 | 0.13 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position reveals a mixed performance. While the Quick Ratio indicates an above-average ability to meet short-term obligations with its most liquid assets, the Current, Cash, and Operating Cash Flow Ratios suggest potential challenges in meeting short-term liabilities. The healthcare industry often requires maintaining sufficient liquidity to manage operational expenses and unforeseen costs. The weighted average calculation highlights recent trends, indicating areas needing attention to ensure financial stability.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.01 | 1.32 | 1.56 | 1.55 | 1.48 |
| Quick Ratio | 0.94 | 1.29 | 1.5 | 1.37 | 1.38 |
| Cash Ratio | 0.14 | 0.29 | 0.31 | 0.12 | 0.14 |
| Operating Cash Flow Ratio | 0.09 | 0.04 | -0.03 | 0.22 | 0.2 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | NGL Fine Chem Ltd | 6.98 | 39.22 | Overvalued | 73.00 | 67.39 | 48.00 |
| 3 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 4 | Kilitch Drugs (India) Ltd | 6.61 | 21.54 | Neutral | 37.00 | 9.27 | 30.00 |
| 5 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 6 | SMS Lifesciences India Ltd | 6.59 | 21.20 | Undervalued | 45.00 | 70.68 | 19.00 |
| 7 | Infinium Pharmachem Ltd | 6.42 | 26.90 | Neutral | 22.00 | 6.43 | 14.00 |
| 8 | Sakar Healthcare Ltd | 5.81 | 58.66 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 9 | Medicamen Biotech Ltd | 5.73 | 32.19 | Neutral | 20.00 | 6.94 | 10.00 |
| 10 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 59.71 | Neutral | 7.00 | 1.40 | 4.00 |
| 11 | Albert David Ltd | 5.63 | -272.47 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | BPL Ltd | 5.46 | -31.11 | Neutral | -4.82 | -3.00 | -8.55 |
| 13 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 14 | Remus Pharmaceuticals Ltd | 5.31 | 25.48 | Neutral | 57.00 | 20.97 | 46.00 |
| 15 | Ind-Swift Laboratories Ltd | 4.95 | 39.28 | Neutral | 45.00 | 4.89 | 41.00 |
| 16 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 17 | Lyka Labs Ltd | 4.77 | -23.98 | Neutral | -4.00 | -9.05 | -10.00 |
| 18 | Wanbury Ltd | 4.65 | 28.62 | Neutral | 88.00 | 18.93 | 43.00 |
| 19 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
The management effectiveness of Kilitch Drugs (India) Ltd is a mix of strengths and weaknesses. The company has shown good compounded profit growth in the past, along with improved returns on capital. However, rising debt and inconsistent quarterly sales and profit growth are concerns. The promoters' stable holding indicates confidence. Overall, management's ability to maintain growth while managing debt will be critical.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Compounded Profit Growth (5Y, 3Y) | 161%, 67% | Strong profit expansion. |
| Return on Capital Employed (ROCE) | 17% | Improving capital efficiency. | |
| Promoter Holding | 69.23% | Stable promoter confidence. | |
| CONS | Debt/Equity Ratio | Increasing Borrowings | Leverage is under control. |
| Quarterly Sales Growth Volatility | Fluctuations | Inconsistent sales performance. | |
| Absence of Institutional Holding (FII/DII) | 0% | Lack of institutional interest. |
Financial Performance & Growth
Kilitch Drugs' financial performance shows mixed signals. Compounded sales growth is positive, but quarterly sales growth is inconsistent. Compounded profit growth is strong over 5 and 3 years but varies in recent quarters. These inconsistencies raise questions about the sustainability of revenue and profit growth. The operating profit margin (OPM) also fluctuates. The company's ability to stabilize its financial performance will be crucial for long-term growth.
| Metric | 2015-2017 | 2018-2020 | 2021-2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Sales Growth (%) | 49.35% | 18.24% | 43.07% | 10.58% | 28.47% |
Capital Efficiency & Returns
Kilitch Drugs' capital efficiency and returns show positive trends. The Return on Capital Employed (ROCE) has been improving, indicating better use of capital. Return on Equity (ROE) has also improved, suggesting better returns to shareholders. The cash conversion cycle, although fluctuating, has recently improved, reflecting better working capital management. The company's ability to maintain and improve these metrics will be crucial for sustainable growth and shareholder value.
| Metric | 2015-2017 | 2018-2020 | 2021-2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| ROCE (%) | - | 4% | 6.67% | 13% | 17% |
Financial Health & Prudence
Kilitch Drugs' financial health is a mix of strengths and weaknesses. The company's borrowings have been increasing, leading to a rise in the debt-to-equity ratio. The dividend payout has been inconsistent. The company's ability to manage its debt levels and maintain a consistent dividend payout policy will be crucial for long-term financial stability.
| Metric | 2015-2017 | 2018-2020 | 2021-2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Borrowings (Cr) | 0.33 | 8.33 | 20.67 | 32 | 49 |
Shareholding & Ownership Structure
Kilitch Drugs' shareholding structure indicates stable promoter confidence. The promoter holding has remained relatively consistent over the years, reflecting the promoters' commitment to the company. However, there is no presence of institutional investors.
| Metric | 2016-2018 | 2019-2021 | 2022-2024 | 2025 |
|---|---|---|---|---|
| Promoter Holding (%) | 65.26 | 68.91 | 68.57 | 69.23 |
| DII Holding (%) | 0.00 | 0.04 | 0.00 | 0.00 |
The risk assessment for Kilitch Drugs indicates a moderate level of risk due to increasing debt levels and fluctuating sales and profit growth. The risk profile is balanced by stable promoter holding.
Segment performance volatility
Kilitch Drugs exhibits segment performance volatility as indicated by fluctuations in quarterly sales and profit growth.
| Quarter | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales Growth (%) | 83.69% | 70.49% | 30.25% | -12.95% | 24.23% | 9.30% | 34.20% | 6.07% | -1.45% | 36.61% |
| Profit Growth (%) | 224% | 142% | -10% | 180% | 26% | 76% | 144% | 2% | 24% | 185% |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10183.50Bullish
- SMA 20182.74Bullish
- SMA 50184.34Bullish
- EMA 10183.95Bullish
- EMA 20183.65Bullish
- EMA 50183.22Bullish
- DEMA 10184.74Bullish
- DEMA 20183.74Bullish
- DEMA 50184.47Bullish
- TEMA 10185.58Bullish
- TEMA 20183.97Bullish
- TEMA 50183.89Bullish
- MACD0.19Bullish
- ADX27.60Strong Trend
- IndicatorValueSignal
- RSI62.84Neutral
- CCI238.23Overbought
- ROC 92.68Bullish
- ROC 143.58Bullish
- ROC 251.37Bullish
- Stoch K56.98Neutral
- Stoch D41.29Neutral
- IndicatorValueSignal
- BB Upper186.39Overbought
- BB Middle182.74Neutral
- BB Lower179.08Neutral
- ATR2.98High Volatility
- IndicatorValueSignal
- MFI69.27Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10183.39Bullish
- SMA 20184.02Bullish
- SMA 50181.04Bullish
- EMA 10184.11Bullish
- EMA 20183.69Bullish
- EMA 50181.90Bullish
- DEMA 10184.71Bullish
- DEMA 20184.50Bullish
- DEMA 50185.61Bullish
- TEMA 10185.42Bullish
- TEMA 20184.18Bullish
- TEMA 50184.32Bullish
- MACD0.59Bullish
- ADX32.70Strong Trend
- IndicatorValueSignal
- RSI59.51Neutral
- CCI114.84Overbought
- ROC 93.59Bullish
- ROC 142.21Bullish
- ROC 253.34Bullish
- Stoch K56.64Neutral
- Stoch D47.07Neutral
- IndicatorValueSignal
- BB Upper188.84Neutral
- BB Middle184.02Neutral
- BB Lower179.20Neutral
- ATR4.39High Volatility
- IndicatorValueSignal
- MFI66.70Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10184.00Bullish
- SMA 20182.38Bullish
- SMA 50179.65Bullish
- EMA 10183.90Bullish
- EMA 20182.62Bullish
- EMA 50177.34Bullish
- DEMA 10184.95Bullish
- DEMA 20185.28Bullish
- DEMA 50187.12Bullish
- TEMA 10184.87Bullish
- TEMA 20184.69Bullish
- TEMA 50N/AN/A
- MACD1.94Bearish
- ADX27.95Strong Trend
- IndicatorValueSignal
- RSI57.42Neutral
- CCI63.21Neutral
- ROC 90.01Bullish
- ROC 142.95Bullish
- ROC 256.99Bullish
- Stoch K39.82Neutral
- Stoch D37.56Neutral
- IndicatorValueSignal
- BB Upper193.89Neutral
- BB Middle182.38Neutral
- BB Lower170.86Neutral
- ATR6.97High Volatility
- IndicatorValueSignal
- MFI60.77Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10181.59Bullish
- SMA 20181.08Bullish
- SMA 50161.98Bullish
- SMA 100160.84Bullish
- SMA 200169.28Bullish
- EMA 10182.11Bullish
- EMA 20178.52Bullish
- EMA 50169.36Bullish
- EMA 100166.46Bullish
- EMA 200169.68Bullish
- DEMA 10184.58Bearish
- DEMA 20186.23Bearish
- DEMA 50178.03Bullish
- DEMA 100165.31Bullish
- DEMA 200164.00Bullish
- TEMA 10183.66Bearish
- TEMA 20185.91Bearish
- TEMA 50186.95Bearish
- TEMA 100172.18Bullish
- TEMA 200158.61Bullish
- MACD5.40Bearish
- ADX32.58Strong Trend
- IndicatorValueSignal
- RSI56.09Neutral
- CCI26.64Neutral
- ROC 140.16Bullish
- ROC 2516.38Bullish
- Stoch K57.31Neutral
- Stoch D60.86Neutral
- IndicatorValueSignal
- BB Upper191.06Neutral
- BB Middle181.08Neutral
- BB Lower171.10Neutral
- ATR10.54Low Volatility
- IndicatorValueSignal
- MFI54.93Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 20159.24Bullish
- SMA 50176.17Bullish
- EMA 20164.96Bullish
- EMA 50169.45Bullish
- DEMA 20164.38Bullish
- DEMA 50164.87Bullish
- TEMA 20171.52Bullish
- TEMA 50156.79Bullish
- MACD1.21Bullish
- ADX19.15Weak Trend
- IndicatorValueSignal
- RSI56.09Neutral
- CCI23.62Neutral
- ROC 1418.11Bullish
- ROC 2511.59Bullish
- Stoch K80.82Overbought
- Stoch D78.55Neutral
- IndicatorValueSignal
- BB Upper191.24Neutral
- BB Middle159.24Neutral
- BB Lower127.25Neutral
- ATR19.92High Volatility
- IndicatorValueSignal
- MFI81.70Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 6159.11Bullish
- SMA 12174.61Bullish
- SMA 24172.45Bullish
- EMA 6163.84Bullish
- EMA 12167.66Bullish
- EMA 24165.38Bullish
- DEMA 6161.01Bullish
- DEMA 12163.53Bullish
- DEMA 24178.72Bullish
- TEMA 6164.66Bullish
- TEMA 12156.31Bullish
- TEMA 24168.35Bullish
- MACD21.00Bearish
- ADX38.94Strong Trend
- IndicatorValueSignal
- RSI55.60Neutral
- CCI51.56Neutral
- ROC 252.77Bullish
- ROC 50122.75Bullish
- Stoch K39.76Neutral
- Stoch D53.21Neutral
- IndicatorValueSignal
- BB Upper221.79Neutral
- BB Middle173.06Neutral
- BB Lower124.34Neutral
- ATR37.81High Volatility
- IndicatorValueSignal
- MFI83.96Overbought